Kangstem Biotech KRX:217730KOSDAQ
강스템바이오텍 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days11
DART filings, 7 days1
Articles tracked16since Sep 11
In Q2 2026, Kangstem Biotech reported revenue of ₩642m, down 37.7% year on year, and an operating loss of ₩6.1bn. Kangstem Biotech (강스템바이오텍) appeared in 11 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Oct 27 with 9 articles. The most common catalyst was contracts & orders (1). It was most often mentioned alongside T&R Biofab.
Filing signals Clinical trial filing 4 quarters of losses Screener
Kangstem Biotech quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩642m | -37.7% | −₩6.1bn | −₩6.2bn |
| Q1 2026 | ₩805m | -15.6% | −₩4.6bn | −₩4.6bn |
| Q3 2025 | ₩485m | -38.1% | −₩4.2bn | −₩4.5bn |
| Q2 2025 | ₩1.0bn | -54.7% | −₩4.4bn | −₩4.8bn |
| Q1 2025 | ₩954m | -25.7% | −₩4.7bn | −₩4.9bn |
| Q3 2024 | ₩783m | -39.1% | −₩4.0bn | −₩4.0bn |
| Q2 2024 | ₩2.3bn | – | −₩4.5bn margin −197.7% | ₩4.6bn |
| Q1 2024 | ₩1.3bn | – | −₩3.8bn margin −298.7% | −₩4.2bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Kangstem Biotech top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest Kangstem Biotech news Korean headlines
-
강스템바이오텍, '오스카' 임상 최종보고서 수령…"주요 결과 일관성 확인"
2 more on this story · 2 outlets
- 강스템바이오텍 "오스카 2a상 CSR 수령…주요 데이터 일관성 확인"MTN · Oct 27 13:15
- 강스템바이오텍, '오스카' 임상 2a상 최종보고서 수령히트뉴스 · Oct 27 13:45
-
강스템바이오텍, 무릎 골관절염 치료제 임상 1/2a상 결과보고서 수령…주가 1934원
1 more on this story · 1 outlets
- 강스템바이오텍, 골관절염 치료제 ‘오스카’ 임상 2a상 최종보고서 수령한국경제 · Oct 27 11:40